A Biologist, enthusiastic in learning the current development of Medicine & Biotechnology sciences | respect-based friendship 🍂🍁🍂
Indonesia
Joined February 2021
- Tweets87.8K
- Following19K
- Followers29.5K
- Likes183K
Sarah, D.Sc 🐣 retweeted
Disease fight disease...using virus to fight cancer...
Cancer cells coated with viral peptides, recruit antiviral immune responses to attack tumors.
Essentially tricking the immune system into recognizing cancer as an infection! #senomune
cancer.gov/news-events/cance…
Based on the basic development processes, this review offers a concise framework for applying single-cell and spatial technologies to decode craniofacial organogenesis and to prioritize actionable targets for next-generation therapies.
sciencedirect.com/science/ar…
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial.
[George B, Singh H, Devoe CE, et al. Nature Medicine. 2026. DOI: 10.1038/s41591-026-04734-7]
A new vaccine against pancreatic cancer, one of the deadliest cancers, prompted an immune response in 99% of the patients whose responses could be measured.
Most pancreatic cancers are driven by mutations in the KRAS gene. The vaccine, called camupepimut and developed by Elicio Therapeutics, is designed to train the immune system's T cells to recognize seven of the most common KRAS mutations.
In a phase 2 trial led by Mayo Clinic oncologist Ben George, 144 patients who had already completed surgery and chemotherapy were randomly assigned to receive the vaccine or to be observed without it. Among the 90 vaccinated patients who could be evaluated, 89 developed T cells that targeted mutated KRAS. In more than 80% of them, the response was over nine times stronger than at baseline.
Patients with the strongest immune responses tended to remain cancer-free for longer. A larger phase 3 trial is planned, and it may include booster doses and combinations with other drugs.
[George B, Singh H, Devoe CE, et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Nature Medicine. 2026. DOI: 10.1038/s41591-026-04734-7]
Sebelum ditransplantasikan, jantung dialiri darah hangat melalui alat pompa yang secara terus-menerus mensuplai Oksigen & elektrolit untuk mempertahankan kehidupan sel-selnya.
Jantung bisa tetap berdenyut meskipun dilepas dari tubuh karena memiliki pusat saraf khusus.
Dysregulation of schizophrenia risk gene TYW5 in the mPFC
÷Gene involvement in Psychology/Psychiatry÷
sciencedirect.com/science/ar…
Sarah, D.Sc 🐣 retweeted
CCR5 is a chemokine receptor on immune cells that helps direct them to infection sites. HIV uses it (with CD4) as a co-receptor to enter cells.
The Δ32 mutation is a 32-bp deletion producing a truncated, non-functional receptor absent from the cell surface. Homozygotes (~1% of Europeans) are highly resistant to R5-tropic HIV; heterozygotes show delayed AIDS progression.
It arose once, at least 6,700–9,000 years ago near the Black Sea/Western Steppe. Positive selection occurred in the Neolithic/Bronze Age, likely from immune modulation amid denser farming populations or earlier pathogens—not the Black Death. Frequency peaks in northern Europe.
Sarah, D.Sc 🐣 retweeted
These instruments are called ocarinas. They imitate the sounds of different animals at the Machu Picchu Museum in Cusco, Peru.
Otak dan jaringan saraf mengendalikan seluruh aktivitas tubuh
Brain. Spinal cord. Peripheral nerves.
Explore the network behind sensation and movement with SciePro’s detailed 3D anatomy model, built for anatomical accuracy.
Licensing → link in the first reply.
#SciePro #Neuroanatomy
Sarah, D.Sc 🐣 retweeted
🚨: Scientists have successfully eliminated HIV from infected cells, using Crispr gene-editing technology
Sarah, D.Sc 🐣 retweeted
🚨: Scientists successfully used gene editing to remove HIV from infected cells in a human.
Even after 19 months, that person had no adverse side effects, and scientists are looking at this as the potential future of medicine.
Sarah, D.Sc 🐣 retweeted
🚨 Scientists in France developed an artificial heart that can adapt to the body's needs.
What if a machine could do more than pump blood?
The French-developed Aeson artificial heart uses sensors and intelligent control systems to adjust blood flow according to the body's changing demands.
Unlike many conventional mechanical devices, it uses specially processed animal tissue in parts that contact the blood, alongside advanced pumping technology designed to mimic the natural heart's movements.
The goal is to help people with severe heart failure whose hearts can no longer pump enough blood. For carefully selected patients, the device can serve as a bridge to a heart transplant.
But there is a catch. The system still depends on external batteries and equipment, and its long-term reliability remains an important consideration.
Could artificial hearts one day help more people survive when donor hearts are unavailable? Scientists are working toward that future, but significant challenges remain.
Source: European Commission. (n.d.). The world's only bioprosthetic auto-regulated artificial heart. CORDIS. European Commission research project
ALT Scientists in France developed an artificial heart that can adapt to the body's needs.** What if a machine could do more than pump blood? The French-developed **Aeson artificial heart** uses sensors and intelligent control systems to adjust blood flow according to the body's changing demands. Unlike many conventional mechanical devices, it uses specially processed animal tissue in parts that contact the blood, alongside advanced pumping technology designed to mimic the natural heart's movements. The goal is to help people with severe heart failure whose hearts can no longer pump enough blood. For carefully selected patients, the device can serve as a bridge to a heart transplant.
PTHrP may play an important role in mediating BMP2-induced chondral-osteogenic differentiation of MSCs by inactivating PI3K–AKT signaling, indicating that PTHrP may be exploited for endochondral cartilage-bone tissue engineering.
sciencedirect.com/science/ar…
Sarah, D.Sc 🐣 retweeted
The claim overstates a real but limited pilot study. Mexican researcher Eva Ramón Gallegos (IPN) used photodynamic therapy (delta-aminolevulinic acid + laser) on cervical HPV.
In 29 Mexico City women (higher dose, two applications), HPV cleared in 100% of those without lesions. Rates were lower (~64% with lesions, ~57% for lesions alone). An earlier phase with ~420 women reached ~85% clearance. Results appear in peer-reviewed papers (e.g., Photochem Photobiol 2017 & 2023).
This is a promising non-invasive option for early cervical infection, not a complete elimination of HPV worldwide. Vaccines remain primary prevention; spontaneous clearance is common. Further trials needed.